


## CLAIMS

What is claimed is:

1. A compound that is 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt of Formula II:



wherein  $\text{R}_1$  is H or lower alkyl and x is a number from 0 to 10.

2. The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt.
3. The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate.
4. The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 1 having an x-ray powder diffraction pattern substantially comprising:

-40-

| #  | 2-Theta | d(A)    | Peak | P%    | Area | Area% | FWHM  |
|----|---------|---------|------|-------|------|-------|-------|
| 1  | 6.760   | 13.0648 | 5106 | 100.0 | 1497 | 100.0 | 0.234 |
| 2  | 8.183   | 10.7953 | 1743 | 34.1  | 435  | 29.1  | 0.200 |
| 3  | 8.560   | 10.3207 | 1866 | 36.5  | 543  | 36.3  | 0.233 |
| 4  | 9.239   | 9.5638  | 234  | 4.6   | 29   | 1.9   | 0.096 |
| 5  | 9.760   | 9.0546  | 972  | 19.0  | 220  | 14.7  | 0.181 |
| 6  | 10.569  | 8.3634  | 156  | 3.1   | 12   | 0.8   | 0.061 |
| 7  | 11.141  | 7.9353  | 178  | 3.5   | 29   | 1.9   | 0.130 |
| 8  | 13.760  | 6.4304  | 266  | 5.2   | 46   | 3.1   | 0.138 |
| 9  | 15.599  | 5.6761  | 338  | 6.6   | 63   | 4.2   | 0.148 |
| 10 | 16.740  | 5.2917  | 433  | 8.5   | 64   | 4.3   | 0.118 |
| 11 | 17.420  | 5.0866  | 1890 | 37.0  | 689  | 46.0  | 0.291 |
| 12 | 20.639  | 4.3000  | 523  | 10.2  | 128  | 8.5   | 0.196 |
| 13 | 21.391  | 4.1505  | 188  | 3.7   | 20   | 1.3   | 0.085 |
| 14 | 22.139  | 4.0119  | 445  | 8.7   | 74   | 4.9   | 0.132 |
| 15 | 31.559  | 2.8326  | 270  | 5.3   | 24   | 1.6   | 0.070 |

5. The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt having a  $^{13}\text{C}$  NMR (solid state) in ppm of: 189.6; 186.2; 71.4; 43.4; 30.1; 28.4; 25.2; 23.1.
6. The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt having a  $^{13}\text{C}$  NMR peak at 25.2 ppm.
7. The crystalline compound of Claim 1, wherein said compound comprises 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt ethanol solvate, wherein  $\text{R}_1$  is ethyl.
8. The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt ethanol solvate having an x-ray powder diffraction pattern substantially comprising:

-41-

| #  | 2-Theta | d(A)    | Peak  | P%    | Area | Area% | FWHM  |
|----|---------|---------|-------|-------|------|-------|-------|
| 1  | 6.899   | 12.8028 | 13186 | 100.0 | 3025 | 100.0 | 0.184 |
| 2  | 8.261   | 10.6945 | 5221  | 39.6  | 931  | 30.8  | 0.143 |
| 3  | 8.838   | 9.9969  | 2057  | 15.6  | 482  | 15.9  | 0.187 |
| 4  | 11.061  | 7.9927  | 785   | 6.0   | 160  | 5.3   | 0.163 |
| 5  | 12.100  | 7.3086  | 1355  | 10.3  | 150  | 4.9   | 0.088 |
| 6  | 13.619  | 6.4964  | 450   | 3.4   | 89   | 2.9   | 0.157 |
| 7  | 17.677  | 5.0132  | 753   | 5.7   | 126  | 4.2   | 0.134 |
| 8  | 18.180  | 4.8755  | 2011  | 15.3  | 588  | 19.4  | 0.234 |
| 9  | 20.840  | 4.2588  | 439   | 3.3   | 40   | 1.3   | 0.072 |
| 10 | 21.334  | 4.1615  | 427   | 3.2   | 67   | 2.2   | 0.125 |

9. The crystalline compound of Claim 8 having a  $^{13}\text{C}$  NMR (solid state) in ppm of: 189.9; 186.7; 71.6; 58.5; 43.2; 29.9; 23.5.
10. The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, ethyl alcohol solvate, having a  $^{13}\text{C}$  NMR peak at 58.5 ppm.
11. The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt methanol solvate.
12. The crystalline compound of Claim 11, having an x-ray powder diffraction pattern substantially comprising:

-42-

| #  | 2-Theta | d(A)    | Peak  | P%    | Area | Area% | FWHM  |
|----|---------|---------|-------|-------|------|-------|-------|
| 1  | 6.896   | 12.8072 | 11991 | 100.0 | 2593 | 100.0 | 0.173 |
| 2  | 8.339   | 10.5940 | 2046  | 17.1  | 334  | 12.9  | 0.131 |
| 3  | 9.219   | 9.5853  | 1438  | 12.0  | 281  | 10.8  | 0.156 |
| 4  | 10.280  | 8.5979  | 632   | 5.3   | 180  | 6.9   | 0.227 |
| 5  | 11.320  | 7.8105  | 1079  | 9.0   | 322  | 12.4  | 0.238 |
| 6  | 15.800  | 5.6044  | 463   | 3.9   | 59   | 2.3   | 0.102 |
| 7  | 16.741  | 5.2913  | 432   | 3.6   | 38   | 1.4   | 0.069 |
| 8  | 18.160  | 4.8809  | 1260  | 10.5  | 599  | 23.1  | 0.380 |
| 9  | 18.702  | 4.7408  | 700   | 5.8   | 184  | 7.1   | 0.210 |
| 10 | 19.816  | 4.4766  | 589   | 4.9   | 94   | 3.6   | 0.127 |
| 11 | 21.724  | 4.0876  | 510   | 4.3   | 96   | 3.7   | 0.150 |

13. The crystalline compound of Claim 12 having a  $^{13}\text{C}$  NMR (solid state) in ppm of: 189.6; 186.2; 71.4; 43.2; 29.6; 23.5.
14. The compound which is 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-propyl alcohol solvate.
- 5 15. The crystalline compound of Claim 14 having an x-ray powder diffraction pattern substantially comprising:

| # | 2-Theta | d(A)    | Peak  | P%    | Area | Area% | FWHM  |
|---|---------|---------|-------|-------|------|-------|-------|
| 1 | 6.899   | 12.8025 | 12371 | 100.0 | 3495 | 100.0 | 0.226 |
| 2 | 7.843   | 11.2637 | 4815  | 38.9  | 1119 | 32.0  | 0.186 |
| 3 | 8.661   | 10.2009 | 1709  | 13.8  | 357  | 10.2  | 0.167 |
| 4 | 11.359  | 7.7833  | 771   | 6.2   | 141  | 4.0   | 0.146 |
| 5 | 12.300  | 7.1900  | 752   | 6.1   | 127  | 3.6   | 0.135 |
| 6 | 13.100  | 6.7528  | 517   | 4.2   | 37   | 1.0   | 0.057 |
| 7 | 18.262  | 4.8540  | 1945  | 15.7  | 596  | 17.1  | 0.245 |
| 8 | 20.721  | 4.2832  | 828   | 6.7   | 279  | 8.0   | 0.269 |
| 9 | 21.740  | 4.0847  | 573   | 4.6   | 146  | 4.2   | 0.203 |

-43-

16. The crystalline compound of Claim 15 having a  $^{13}\text{C}$  NMR (solid state) in ppm of: 189.6; 186.2; 71.4; 43.2; 29.6; 23.5.
17. The compound which is 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt 2-propyl alcohol solvate.
- 5 18. The crystalline compound of Claim 17 having an x-ray powder diffraction pattern substantially comprising:

| # | 2-Theta | d(A)    | Peak  | P%    | Area | Area% | FWHM  |
|---|---------|---------|-------|-------|------|-------|-------|
| 1 | 6.918   | 12.7674 | 10028 | 100.0 | 2562 | 100.0 | 0.204 |
| 2 | 8.000   | 11.0427 | 3984  | 39.7  | 800  | 31.2  | 0.161 |
| 3 | 8.619   | 10.2506 | 1619  | 16.1  | 346  | 13.5  | 0.171 |
| 4 | 11.338  | 7.7981  | 658   | 6.6   | 68   | 2.6   | 0.082 |
| 5 | 11.718  | 7.5459  | 236   | 2.4   | 28   | 1.1   | 0.093 |
| 6 | 12.241  | 7.2243  | 761   | 7.6   | 131  | 5.1   | 0.138 |
| 7 | 15.382  | 5.7557  | 610   | 6.1   | 107  | 4.2   | 0.140 |
| 8 | 18.162  | 4.8803  | 1937  | 19.3  | 441  | 17.2  | 0.182 |
| 9 | 20.779  | 4.2713  | 853   | 8.5   | 222  | 8.6   | 0.208 |

19. The crystalline compound of Claim 14 having a  $^{13}\text{C}$  NMR (solid state) in ppm of: 189.4; 187.7; 70.9; 69.4; 66.5; 63.8; 43.2; 35.0; 30.1; 23.8; 18.7; 14.3.
- 10 20. The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 2-propyl alcohol solvate having a  $^{13}\text{C}$  NMR peak at 63.8, 18.7, or 14.3 ppm.
21. The compound which is 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-butyl alcohol solvate.

1003631 424704

-44-

22. The crystalline compound of Claim 21 having an x-ray powder diffraction pattern substantially comprising:

| #  | 2-Theta | d(A)    | Peak  | P%    | Area | Area% | FWHM  |
|----|---------|---------|-------|-------|------|-------|-------|
| 1  | 7.060   | 12.5101 | 19609 | 100.0 | 4796 | 100.0 | 0.196 |
| 2  | 9.078   | 9.7332  | 3027  | 15.4  | 567  | 11.8  | 0.150 |
| 3  | 11.100  | 7.9644  | 924   | 4.7   | 164  | 3.4   | 0.142 |
| 4  | 16.361  | 5.4135  | 554   | 2.8   | 76   | 1.6   | 0.109 |
| 5  | 18.040  | 4.9133  | 2276  | 11.6  | 456  | 9.5   | 0.160 |
| 6  | 18.820  | 4.7112  | 1303  | 6.6   | 385  | 8.0   | 0.236 |
| 7  | 19.922  | 4.4532  | 1886  | 9.6   | 457  | 9.5   | 0.193 |
| 8  | 21.560  | 4.1183  | 853   | 4.4   | 205  | 4.3   | 0.191 |
| 9  | 22.281  | 3.9867  | 343   | 1.7   | 37   | 0.8   | 0.086 |
| 10 | 23.521  | 3.7793  | 450   | 2.3   | 107  | 2.2   | 0.189 |

23. The compound of Claim 21 having a  $^{13}\text{C}$  NMR (solid state) in ppm of:  
189.9: 186.0: 71.6: 43.2: 29.9: 23.8.

5


24. The compound 6-(5-carboxy-5-mentyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 2 having an x-ray powder diffraction pattern substantially comprising:

-45-


| #  | 2-Theta | d(A)    | Peak | P%    | Area | Area% | FWHM  |
|----|---------|---------|------|-------|------|-------|-------|
| 1  | 7.259   | 12.1686 | 9283 | 100.0 | 2482 | 100.0 | 0.214 |
| 2  | 8.739   | 10.1100 | 4191 | 45.1  | 603  | 24.3  | 0.115 |
| 3  | 9.386   | 8.9628  | 967  | 10.4  | 161  | 6.5   | 0.133 |
| 4  | 11.659  | 7.5838  | 430  | 4.6   | 49   | 1.9   | 0.089 |
| 5  | 13.955  | 6.3408  | 305  | 3.3   | 58   | 2.3   | 0.151 |
| 6  | 14.220  | 6.2233  | 326  | 3.5   | 73   | 2.9   | 0.178 |
| 7  | 15.387  | 5.7537  | 278  | 3.0   | 19   | 0.7   | 0.053 |
| 8  | 16.461  | 5.3806  | 986  | 10.6  | 187  | 7.5   | 0.152 |
| 9  | 17.361  | 5.1039  | 1490 | 16.1  | 348  | 14.0  | 0.187 |
| 10 | 18.063  | 4.9069  | 1284 | 13.8  | 323  | 13.0  | 0.201 |
| 11 | 19.302  | 4.5947  | 871  | 9.4   | 166  | 6.7   | 0.152 |
| 12 | 19.862  | 4.4664  | 686  | 7.4   | 142  | 5.7   | 0.166 |
| 13 | 20.200  | 4.3923  | 457  | 4.9   | 103  | 4.1   | 0.179 |
| 14 | 21.178  | 4.1918  | 656  | 7.1   | 97   | 3.9   | 0.117 |
| 15 | 21.641  | 4.1031  | 167  | 1.8   | 6    | 0.2   | 0.029 |
| 16 | 22.300  | 3.9833  | 794  | 8.6   | 192  | 7.7   | 0.193 |
| 17 | 23.218  | 3.8278  | 247  | 2.7   | 23   | 0.9   | 0.071 |
| 18 | 24.100  | 3.6897  | 183  | 2.0   | 34   | 1.3   | 0.145 |
| 19 | 25.481  | 3.4928  | 487  | 5.2   | 141  | 5.7   | 0.231 |
| 20 | 28.800  | 3.0974  | 134  | 1.4   | 14   | 0.6   | 0.083 |
| 21 | 29.297  | 3.0459  | 259  | 2.8   | 28   | 1.1   | 0.084 |
| 22 | 30.700  | 2.9099  | 287  | 3.1   | 20   | 0.8   | 0.055 |

25. The crystalline compound of Claim 24 having a  $^{13}\text{C}$  NMR (solid state) in ppm of 190.9; 189.6; 186.2; 120.4; 72.7; 44.7; 44.2; 43.0; 42.3; 39.3; 37.9; 31.8; 30.9; 29.6; 27.7; 26.2; 25.3; 24.0; 22.9; 21.5; and 20.2.
26. The compound 6-(5-carboxy-5-mentyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 2 having a  $^{13}\text{C}$  NMR peak at 72.7, 44.7, or 26.2 ppm.

27. The compound of Claim 1, wherein said crystalline structure contains from approximately 0.1 to approximately 1.0 water molecules per salt ion.
28. A method for preparing a stable crystalline compound of Formula II:



- 5 wherein R<sub>1</sub> is lower alkyl and x is a number from 0 to 10, comprising reacting a compound of Formula I



10 with calcium oxide in an alkanol organic solvent of the formula R<sub>1</sub>OH to yield a solid product; and drying the solid product to obtain the monocalcium dicarboxylate ether salt of the compound of Formula II having a stoichiometric ratio of calcium to dicarboxylate of approximately 1:1.

29. The method of Claim 28, wherein the organic solvent is a C<sub>1</sub>-C<sub>12</sub> alcohol.
30. The method of Claim 28, wherein the C<sub>1</sub>-C<sub>12</sub> alcohol is essentially anhydrous.
31. The method of Claim 28, wherein the alcohol is a C<sub>1</sub>-C<sub>4</sub> alkanol.
32. The method of Claim 28 further comprising the step of introducing a work-up solvent into the organic alcohol solvent, wherein the work-up solvent causes at least a portion of the monocalcium dicarboxylate ether salt to precipitate from the organic alcohol solvent.



-47-

33. The method of Claim 32 wherein the work-up solvent is methyl *tert*-butyl ether.
34. The method of Claim 32 further comprising the step of filtering the solid product from the organic solvent prior to drying.
- 5 35. The method of Claim 32 further comprising the step of washing the solid product with the organic work-up solvent subsequent to filtering.
36. A method for preparing a crystalline hydrate of the Formula II
- $$\begin{array}{c}
 \text{O}^- \\
 | \\
 \text{C} \\
 || \\
 \text{O}
 \end{array}
 - \begin{array}{c}
 \text{CH}_3 \\
 | \\
 \text{C} \\
 | \\
 \text{CH}_3
 \end{array}
 - (\text{CH}_2)_4 - \text{O} - (\text{CH}_2)_4 - \begin{array}{c}
 \text{CH}_3 \\
 | \\
 \text{C} \\
 | \\
 \text{CH}_3
 \end{array}
 - \begin{array}{c}
 \text{O}^- \\
 | \\
 \text{C} \\
 || \\
 \text{O}
 \end{array}
 \cdot \text{Ca}^{++} \cdot x\text{R}_1\text{OH} \quad \text{II}$$
- wherein R<sub>1</sub> is H and x is a number from 0 to 10, comprising reacting an alcohol solvate of Formula II where R<sub>1</sub> is lower alkyl with water.
- 10 37. The method of Claim 36 wherein the solid product contains between approximately 0.1 and approximately 1.0 equivalents of water per equivalent of the monocalcium dicarboxylate ether salt subsequent to said filtering step and said drying step.
- 15 38. The method of Claim 28 wherein said reacting step occurs at a temperature between about 15°C and the reflux point of the alkanol organic solvent at standard pressure.
39. The method of Claim 28 wherein said reacting step occurs at a temperature between the reflux point of the alkanol organic solvent and about 150°C at a pressure above standard pressure.
- 20 40. A method of converting the compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate Crystal Form 1 into the compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic

-48-

- acid monocalcium salt hydrate Crystal Form 2. said method comprising the steps of: exposing the Crystal Form 1 to water; agitating the Crystal Form 1 and water; heating the Crystal Form 1 and water for sufficient time for a conversion to occur so as to yield Crystal Form 2; and drying the solid product to obtain the 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate Crystal Form 2. wherein the Crystal Form 2 has a stoichiometric ratio of calcium to dicarboxylate form of the compound of 1:1.
- 5
41. The method of Claim 40 further comprising the step of filtering the Crystal Form 2 from the water prior to said drying step.
- 10
42. A pharmaceutical composition comprising the compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt together with one or more pharmaceutically acceptable diluents, carriers or excipients.
- 15
43. A pharmaceutical composition comprising a crystalline form 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt together with one or more pharmaceutically acceptable diluents, carriers or excipients.
- 20
44. A pharmaceutical composition comprising 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate Crystal Form 1 together with one or more pharmaceutically acceptable diluents, carriers or excipients.
- 25
45. A pharmaceutical composition comprising 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate Crystal Form 2 together with one or more pharmaceutically acceptable diluents, carriers or excipients.

-49-

46. The use of a compound as set forth in Claim 1 for the treatment of vascular disease.
47. The use of a compound as set forth in Claim 1 for the treatment of diabetes.
- 5 48. A compound according to Claim 1 substantially as described herein in any of the examples.
49. A method of treating a vascular disease in a patient in need thereof, said method comprising administering to the patient a therapeutically effective amount of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt.
- 10 50. A method according to Claim 49, wherein the compound is Crystal Form I having an x-ray powder diffraction pattern substantially comprising:

| #  | 2-Theta | d(A)    | Peak | P%    | Area | Area% | FWHM  |
|----|---------|---------|------|-------|------|-------|-------|
| 1  | 6.760   | 13.0648 | 5106 | 100.0 | 1497 | 100.0 | 0.234 |
| 2  | 8.183   | 10.7953 | 1743 | 34.1  | 435  | 29.1  | 0.200 |
| 3  | 8.560   | 10.3207 | 1866 | 36.5  | 543  | 36.3  | 0.233 |
| 4  | 9.239   | 9.5638  | 234  | 4.6   | 29   | 1.9   | 0.096 |
| 5  | 9.760   | 9.0546  | 972  | 19.0  | 220  | 14.7  | 0.181 |
| 6  | 10.569  | 8.3634  | 156  | 3.1   | 12   | 0.8   | 0.061 |
| 7  | 11.141  | 7.9353  | 178  | 3.5   | 29   | 1.9   | 0.130 |
| 8  | 13.760  | 6.4304  | 266  | 5.2   | 46   | 3.1   | 0.138 |
| 9  | 15.599  | 5.6761  | 338  | 6.6   | 63   | 4.2   | 0.148 |
| 10 | 16.740  | 5.2917  | 433  | 8.5   | 64   | 4.3   | 0.118 |
| 11 | 17.420  | 5.0866  | 1890 | 37.0  | 689  | 46.0  | 0.291 |
| 12 | 20.639  | 4.3000  | 523  | 10.2  | 128  | 8.5   | 0.196 |
| 13 | 21.391  | 4.1505  | 188  | 3.7   | 20   | 1.3   | 0.085 |
| 14 | 22.139  | 4.0119  | 445  | 8.7   | 74   | 4.9   | 0.132 |
| 15 | 31.559  | 2.8326  | 270  | 5.3   | 24   | 1.6   | 0.070 |

-50-

51. A method according to Claim 49, wherein the compound is Crystal Form 2 having an x-ray powder diffraction pattern substantially comprising:

| #  | 2-Theta | d(A)    | Peak | P%    | Area | Area% | FWHM  |
|----|---------|---------|------|-------|------|-------|-------|
| 1  | 7.259   | 12.1686 | 9283 | 100.0 | 2482 | 100.0 | 0.214 |
| 2  | 8.739   | 10.1100 | 4191 | 45.1  | 603  | 24.3  | 0.115 |
| 3  | 9.3860  | 8.9628  | 967  | 10.4  | 161  | 6.5   | 0.133 |
| 4  | 11.659  | 7.5838  | 430  | 4.6   | 49   | 1.9   | 0.089 |
| 5  | 13.955  | 6.3408  | 305  | 3.3   | 58   | 2.3   | 0.151 |
| 6  | 14.220  | 6.2233  | 326  | 3.5   | 73   | 2.9   | 0.178 |
| 7  | 15.387  | 5.7537  | 278  | 3.0   | 19   | 0.7   | 0.053 |
| 8  | 16.461  | 5.3806  | 986  | 10.6  | 187  | 7.5   | 0.152 |
| 9  | 17.361  | 5.1039  | 1490 | 16.1  | 348  | 14.0  | 0.187 |
| 10 | 18.063  | 4.9069  | 1284 | 13.8  | 323  | 13.0  | 0.201 |
| 11 | 19.302  | 4.5947  | 871  | 9.4   | 166  | 6.7   | 0.152 |
| 12 | 19.862  | 4.4664  | 686  | 7.4   | 142  | 5.7   | 0.166 |
| 13 | 20.200  | 4.3923  | 457  | 4.9   | 103  | 4.1   | 0.179 |
| 14 | 21.178  | 4.1918  | 656  | 7.1   | 97   | 3.9   | 0.117 |
| 15 | 21.641  | 4.1031  | 167  | 1.8   | 6    | 0.2   | 0.029 |
| 16 | 22.300  | 3.9833  | 794  | 8.6   | 192  | 7.7   | 0.193 |
| 17 | 23.218  | 3.8278  | 247  | 2.7   | 23   | 0.9   | 0.071 |
| 18 | 24.100  | 3.6897  | 183  | 2.0   | 34   | 1.3   | 0.145 |
| 19 | 25.481  | 3.4928  | 487  | 5.2   | 141  | 5.7   | 0.231 |
| 20 | 28.800  | 3.0974  | 134  | 1.4   | 14   | 0.6   | 0.083 |
| 21 | 29.297  | 3.0459  | 259  | 2.8   | 28   | 1.1   | 0.084 |
| 22 | 30.700  | 2.9099  | 287  | 3.1   | 20   | 0.8   | 0.055 |